Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon

Journal of Virology

Volumn 76, Issue 24, 2002, Pages 12775-12782

  Wu, Hongju ^a   Dmitriev, Igor ^a   Kashentseva, Elena ^a   Seki, Toshiro ^a   Wang, Minghui ^a   Curiel, David T ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY;

ADENOVIRUS; ARTICLE; CONTROLLED STUDY; EMBRYO; GENE TARGETING; GENE TRANSFER; HELA CELL; HEXON GENE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; PRIORITY JOURNAL; SEROTYPE; VIRAL GENE THERAPY; VIRUS GENE; VIRUS STRAIN;

ADENOVIRIDAE; ANIMALS; CHIMERA; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEAT; HELA CELLS; HUMANS; MICE; MICE, INBRED C57BL; SEROTYPING; VIRUS ASSEMBLY;

EID: 0036891828     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.24.12775-12782.2002     Document Type: Article

References (41)

1. Athappilly, F. K., R. Murali, J. J. Rux, Z. Cai, and R. M. Burnett. 1994. The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 Å resolution. J. Mol. Biol. 242:430-455.
2. Barnett, B. G., C. J. Crews, and J. T. Douglas. 2002. Targeted adenoviral vectors. Biochim. Biophys. Acta 1575:1-14.
3. Benko, M., B. Harrach, and W. C. Russell. 1999. Family adenoviridae, p. 227-238. In M. H. Van Regenmortel, C. M. Fauquet, D. H. L. Bishop, E. B. Carstens, M. K. Estes, S. M. Lemon, J. Maniloff, M. A. Mayo, D. J. McGeoch, C. R. Pringle, and R. B. Wickner (ed.), Virus Taxonomy. Seventh Report of the International Committee on Taxonomy of Viruses. Academic Press, Inc., New York, N.Y.
4. Crawford-Miksza, L., and D. P. Schnurr. 1996. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J. Virol. 70:1836-1844.
5. Croyle, M. A., N. Chirmule, Y. Zhang, and J. M. Wilson. 2001. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75:4792-4801.
6. Dai, Y., E. M. Schwarz, D. Gu, W. W. Zhang, N. Sarvetneck, and I. M. Verma. 1995. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA 92:1401-1405.
7. De Jong, J. C., A. G. Wermenbol, M. W. Verweij-Uijterwaal, K. W. Slaterus, P. Wertheim-Van Dillen, G. J. Van Doornum, S. H. Khoo, and J. C. Hierholzer. 1999. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J. Clin. Microbiol. 37: 3940-3945.
8. D'Halluin, J. C. 1995. Virus assembly. Curr. Top. Microbiol. Immunol. 199:47-66.
9. Dmitriev, I., V. Krasnykh, C. R. Miller, M. Wang, E. Kashentseva, G. Mikheeva, N. Belousova, and D. T. Curiel. 1998. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72:9706-9713.
10. Dmitrievi I. P., E. A. Kashentseva, and D. T. Curiel. 2002. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J. Virol. 76:6893-6899.
11. Everitt, E., B. Sundquist, U. Pettersson, and L. Philipson. 1973. Structural proteins of adenoviruses. X. Isolation and topography of low molecular weight antigens from the virion of adenovirus type 2. Virology 52:130-147.
12. Frost, E., and J. Williams. 1978. Mapping temperature-sensitive and host-range mutations of adenovirus type 5 by marker rescue. Virology 91:39-50.
13. Gahery-Segard, H., F. Farace, D. Godfrin, J. Gaston, R. Lengagne, T. Tursz, P. Boulanger, and J. G. Guillet. 1998. Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 72:2388-2397.
14. Gall, J., A. Kass-Eisler, L. Leinwand, and E. Falck-Pedersen. 1996. Adenovirus type 5 and 7 capsid chimera: Fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J. Virol. 70:2116-2123.
15. Gall, J. G., R. G. Crystal, and E. Falck-Pedersen. 1998. Construction and characterization of hexon-chimeric adenoviruses: Specification of adenovirus serotype. J. Virol. 72:10260-10264.
16. Harvey, B. G., N. R. Hackett, T. El-Sawy, T. K. Rosengart, E. A. Hirschowitz, M. D. Lieberman, M. L. Lesser, and R. G. Crystal. 1999. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J. Virol. 73:6729-6742.
17. Jooss, K., L. A. Turka, and J. M. Wilson. 1998. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther. 5:309-319.
18. Molinier-Frenkel, V., R. Lengagne, F. Gaden, S. S. Hong, J. Choppin, H. Gahery-Segard, P. Boulanger, and J. G. Guillet. 2002. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol. 76:127-135.
19. Nemerow, G. R. 2000. Adenoviral vectors - New insights. Trends Microbiol. 8:391-394.
20. O'Riordan, C. R., A. Lachapelle, C. Delgado, V. Parkes, S. C. Wadsworth, A. E. Smith, and G. E. Francis. 1999, PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 10:1349-1358.
21. Ostapchuk, P., and P. Hearing. 2001. Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E. J. Virol. 75:45-51.
22. Ritter, T., M. Lehmann, and H. Volk. 2002. Improvements in gene therapy: Averting the immune response to adenoviral vectors. BioDrugs 16:3-10.
23. Roberts, M. M., J. L. White, M. G. Grutter, and R. M. Burnett. 1986. Three-dimensional structure of the adenovirus major coat protein hexon. Science 232:148-1151.
24. Roy, S., P. S. Shirley, A. McClelland, and M. Kaleko. 1998. Circumvention of immunity to the adenovirus major coat protein hexon. J. Virol. 72:6875-6879.
25. Rux, J. J., and R. M. Burnett. 2000. Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol. Ther. 1:18-30.
26. Seki, T., I. Dmitriev, K. Suzuki, E. Kashentseva, K. Takayama, M. Rots, T. Uil, H. Wu, M. Wang, and D. T. Curiel. 2002. Fiber shaft extension in combination with HI loop ligands augments infectivity for CAR-negative tumor targets but does not enhance hepatotropism in vivo. Gene Ther. 9:1101-1108.
27. Sharpe, S., A. Fooks, J. Lee, K. Hayes, C. Clegg, and M. Cranage. 2002. Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses. Virology 293:210-216.
28. Shenk, T. 1996. Adenoviridae: The viruses and their replication, p. 2111-2148. In B. N. Fields, D. M. Knipe, P. M. Howley, et al. (ed.), Fields Virology, 3rd Ed. Lippincott-Raven Publishers, Philadelphia, Pa.
29. Smith, T. A., B. D. White, J. M. Gardner, M. Kaleko, and A. McClelland. 1996. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther. 3:496-502.
30. Stewart, P. L., and R. M. Burnett. 1995. Adenovirus structure by X-ray crystallography and electron microscopy. Curr. Top. Microbiol. Immunol. 199:25-38.
31. van Oostrum, J., P. R. Smith, M. Mohraz, and R. M. Burnett. 1987. The structure of the adenovirus capsid. III. Hexon packing determined from electron micrographs of capsid fragments. J. Mol. Biol. 198:73-89.
32. Vorburger, S. A., and K. K. Hunt. 2002. Adenoviral gene therapy. Oncologist 7:46-59.
33. Wickham, T. J., P. W. Roelvink, D. E. Brough, and I. Kovesdi. 1996. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat. Biotechnol. 14:1570-1573.
34. Wickham, T. J., E. Tzeng, L. L. Shears II, P. W. Roelvink, Y. Li, G. M. Lee, D. E. Brough, A. Lizonova, and I. Kovesdi. 1997. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71:8221-8229.
35. Wohlfart, C. 1988. Neutralization of adenoviruses: Kinetics, stoichiometry, and mechanisms. J. Virol. 62:2321-2328.
36. Wu, H., T. Seki, I. Dmitriev, T. Uil, E. Kashentseva, T. Han, and D. T. Curiel. 2002. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum. Gene Ther. 13:1647-1653.
37. Yang, Y., S. E. Haecker, Q. Su, and J. M. Wilson. 1996. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum. Mol. Genet. 5:1703-1712.
38. Yang, Y., Q. Li, H. C. Ertl, and J. M. Wilson. 1995. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69:2004-2015.
39. Yang, Y., Q. Su, I. S. Grewal, R. Schilz, R. A. Flavell, and J. M. Wilson. 1996. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J. Virol. 70:6370-6377.
40. Youil, R., T. J. Toner, Q. Su, M. Chen, A. Tang, A. J. Bett, and D. Casimiro. 2002. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum. Gene Ther. 13:311-320.
41. Zaiss, A. K., Q. Liu, G. P. Bowen, N. C. Wong, J. S. Bartlett, and D. A. Muruve. 2002. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 76:4580-4590.